Financial Performance - Achieved net product revenue of $11.2 million for AVMAPKI™ FAKZYNJA™ CO-PACK in Q3 2025, marking the first full quarter since its launch[1][4][15] - Total revenue for the three months ended September 30, 2025, was $11,242,000, compared to $0 for the same period in 2024[39] - Net loss for Q3 2025 was $98.5 million, or $1.35 per share, compared to a net loss of $24.0 million, or $0.60 per share, in Q3 2024[1][19] - The net loss for the three months ended September 30, 2025, was $98,518,000, compared to a net loss of $23,967,000 for the same period in 2024[39] - Adjusted net loss (non-GAAP) for Q3 2025 was $39.354 million, compared to $35.278 million in Q3 2024, indicating a slight increase in adjusted losses[43] - Net loss per share (diluted, GAAP) for Q3 2025 was $(1.35), compared to $(0.60) in Q3 2024, reflecting a worsening loss per share[43] - For the nine months ended September 30, 2025, the net loss was $176.555 million, compared to $66.086 million for the same period in 2024[43] - The total adjusted net loss for the nine months ended September 30, 2025, was $123.765 million, compared to $78.002 million for the same period in 2024[43] Cash and Expenses - Ended Q3 2025 with cash and cash equivalents of $137.7 million, with an expected cash runway extending into the second half of 2026[1][20] - Research and development expenses increased by $4.2 million, or 16.9%, to $29.0 million in Q3 2025, primarily due to higher drug substance and trial costs[1][17] - Selling, general, and administrative expenses rose by $8.7 million, or 70.7%, to $21.0 million in Q3 2025, driven by commercialization costs for AVMAPKI FAKZYNJA[1][18] - Total operating expenses for the nine months ended September 30, 2025, were $142,033,000, compared to $93,366,000 for the same period in 2024[39] - Stock-based compensation expense for Q3 2025 was $2.178 million, up from $1.935 million in Q3 2024[43] Clinical Trials and Research - Preliminary safety and efficacy data for VS-7375 showed no dose-limiting toxicities in the ongoing Phase 1/2a trial, with four out of five patients experiencing tumor reduction[1][8] - Enrollment for the combination cohort of VS-7375 with cetuximab in advanced solid tumors has been initiated[1][8] - The company expects to report updates on the safety and efficacy of the RAMP 205 expansion cohort in 1H 2026[1][11] - The ongoing Phase 3 RAMP 301 trial completed enrollment of 270 patients a quarter early, with an additional 29 patients to be added based on IDMC recommendations[1][8] - The company is conducting RAMP 301, an international Phase 3 confirmatory trial for the combination of avutometinib and defactinib[24] - Verastem initiated a Phase 1/2a clinical trial for VS-7375, a KRAS G12D dual ON/OFF inhibitor, in June 2025[32] Regulatory and Collaborations - AVMAPKI™ FAKZYNJA™ CO-PACK received FDA approval for treating adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) on May 8, 2025[24] - The company plans to engage with the FDA regarding potential registration-directed clinical trials in PDAC and NSCLC in 1H 2026[1][12] - The collaboration with GenFleet Therapeutics aims to advance three oncology discovery programs related to RAS/MAPK pathway-driven cancers[33]

Core Insights - Verastem, Inc. (NASDAQ: VSTM) reported positive preliminary results from a phase 1/2a dose-escalation trial of VS-7375, an oral KRAS G12D inhibitor, in patients with KRAS G12D-mutant solid tumors [1][2] Group 1: Trial Results - The preliminary safety and tolerability data indicate that VS-7375 can be administered at efficacious doses while managing gastrointestinal side effects [2] - Anti-tumor activity has been observed among pre-treated patients with advanced pancreatic cancer and other solid tumors [3] - The company has initiated patient enrollment for the first dose-escalation combination cohort and plans to evaluate VS-7375 in combination with cetuximab [3][4] Group 2: Future Plans - Subject to the outcome of the Phase 1 dose escalation, Verastem intends to initiate a combination expansion cohort in colorectal cancer [4] - The company plans to select the recommended Phase 2 dose and advance subsequent efficacy and safety analysis in patients with advanced pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) [4] Group 3: Company Overview - Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing new medicines for cancers driven by the RAS/MAPK signaling pathway [5] - The company develops novel small-molecule drugs, including inhibitors targeting RAF/MEK, FAK, and KRAS G12D [5]

Industry Overview - The global cancer treatment market is undergoing a transformative phase due to rising cancer incidence and rapid scientific advancements, with the U.S. projected to report 2.04 million new cancer cases and over 618,000 deaths in 2025 [1] - An aging population and lifestyle-related risks are increasing global cancer prevalence, leading to higher oncology spending by healthcare systems [1] Innovation in Cancer Treatment - Advances in immunotherapies, targeted drugs, and personalized vaccines are expanding treatment options beyond traditional chemotherapy and radiation [2] - Immune-based approaches, such as checkpoint inhibitors and CAR-T therapies, enhance the body's defenses against tumors, while targeted therapies focus on specific genetic mutations to improve precision and reduce side effects [2] - Emerging technologies like genomic sequencing, AI, and machine learning are accelerating biomarker discovery and improving early detection, contributing to better survival rates and quality of life across many cancer types [3] Pharmaceutical Investment - Major pharmaceutical companies, including Novartis, AstraZeneca, Johnson & Johnson, Pfizer, AbbVie, Merck, Bristol Myers Squibb, and Eli Lilly, are aggressively investing in new oncology pipelines, including antibody-drug conjugates and next-generation immuno-oncology agents [4] - Smaller biotech firms are key sources of innovation, driving collaborations, licensing deals, and acquisitions as larger companies seek novel assets [4] Investment Opportunities - The oncology segment is positioned as one of the most attractive and resilient areas for long-term investors due to continued innovation and favorable reimbursement trends [5] - Stocks such as Relay Therapeutics, Fate Therapeutics, and Verastem Oncology are highlighted as potential investment opportunities in the rising cancer treatment trend [6] Company Highlights - **Relay Therapeutics** is developing RLY-2608, a mutant-selective PI3Kα inhibitor, showing potential benefits in clinical studies for advanced breast cancer [7][8] - **Fate Therapeutics** focuses on universal, off-the-shelf cell products and is co-developing FT825/ONO-8250, a CAR T-cell product candidate, with promising safety profiles in early studies [9][10][11] - **Verastem Oncology** received FDA approval for its combination regimen of avutometinib and defactinib for treating KRAS mutant recurrent low-grade serous ovarian cancer, generating $2.1 million in sales shortly after launch [12][13]

Core Viewpoint - Verastem (VSTM) shares have recently declined by 16.4% over the past week, but the formation of a hammer chart pattern suggests potential support and a possible trend reversal in the future [1][2]. Technical Analysis - The hammer chart pattern indicates a nearing bottom with likely subsiding selling pressure, suggesting a bullish case for the stock [2]. - A hammer pattern is characterized by a small candle body with a long lower wick, indicating that despite a downtrend, buying interest has emerged to push the stock price up towards the opening price [4][5]. - The occurrence of a hammer pattern at the bottom of a downtrend signals that bears may have lost control, indicating a potential trend reversal [5]. Fundamental Analysis - Recent upward revisions in earnings estimates for VSTM enhance the prospects for a trend reversal, as trends in earnings estimate revisions are strongly correlated with near-term stock price movements [7]. - Over the last 30 days, the consensus EPS estimate for the current year has increased by 2.4%, indicating that sell-side analysts expect better earnings than previously predicted [8]. - VSTM holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10].

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its third quarter 2025 financial results and business updates on Tuesday, November 4, 2025, at 8:00 am ET. To access the conference call, please dial (888) 596-4144 (U.S.) or (646) 968-2525 (international) and enter the passcode 8194537 at. ...

Core Insights - Three stocks are highlighted with strong momentum characteristics and a buy rank as of October 21, including Verastem, Inc., Amer Sports, Inc., and Sono-Tek Corporation [1][2][3] Company Summaries - **Verastem, Inc. (VSTM)**: - Zacks Rank 1 - Current year earnings estimate increased by 21.5% over the last 60 days - Shares gained 52.2% over the last three months, outperforming the S&P 500's 5.7% increase - Momentum Score of A [1] - **Amer Sports, Inc. (AS)**: - Zacks Rank 1 - Current year earnings estimate increased by 9.1% over the last 60 days - Shares gained 38.7% over the past six months, compared to the S&P 500's 26.2% increase - Momentum Score of A [2] - **Sono-Tek Corporation (SOTK)**: - Zacks Rank 1 - Current year earnings estimate increased by 37.5% over the last 60 days - Shares gained 15.9% over the last three months, outperforming the S&P 500's 5.7% increase - Momentum Score of A [3]

Core Insights - Five stocks have been added to the Zacks Rank 1 (Strong Buy) List, indicating strong potential for investment returns Group 1: Company Earnings Estimates - Newmont Corporation (NEM) has seen a 6.9% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Royal Bank of Canada (RY) has experienced a 5.6% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Amer Sports, Inc. (AS) has seen a 9.1% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Verastem, Inc. (VSTM) has experienced a significant 21.5% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Sono-Tek Corporation (SOTK) has seen a remarkable 37.5% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [3]

Core Insights - Verastem Oncology is collaborating with GenFleet Therapeutics to develop GFH375 (VS-7375) for advanced KRAS G12D mutant pancreatic ductal adenocarcinoma, aiming to provide new treatment options for patients with limited choices [1][6] - RBC Capital maintains an "Outperform" rating on Verastem's stock, currently trading at $8.32, with a price target of $13, indicating a potential increase of 62.3% [2][5] - Despite a negative price-to-earnings (P/E) ratio of -3.38 and an enterprise value to operating cash flow ratio of -3.62, the company's strong current ratio of 3.46 suggests a solid ability to meet short-term liabilities [2][3][4] Financial Metrics - The debt-to-equity ratio of Verastem stands at 2.09, indicating a higher level of debt compared to equity [4] - The ongoing study with GenFleet Therapeutics could significantly enhance Verastem's market position and financial outlook if successful [4][5] - RBC Capital's positive outlook reflects confidence in Verastem's strategic initiatives and potential breakthroughs in oncology [5][6]

Core Insights - Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for cancer patients, attracting attention from momentum investors due to its recent performance and analyst projections [1] Price Targets and Performance - RBC Capital set a price target of $13 for Verastem, indicating a potential increase of 62.3% from the current stock price of $8.01 [2][6] - Zacks Investment Research assigned Verastem a Momentum Style Score of A, suggesting strong potential for continued positive performance, with a current trading price of $9.22 and a 1.9% gain over the past four weeks [3][6] - Wall Street analysts have a price target range for Verastem from $13 to $20, indicating potential increases of 41% to 116.9% [5][6] Stock Performance and Market Data - The stock price has recently decreased by 7.97% to $8.49, with a trading range today between $6.98 and $9.02, and a yearly range from a low of $2.95 to a high of $11.25 [4] - Verastem's market capitalization is approximately $522.2 million, with a trading volume of 4,762,954 shares on the NASDAQ exchange [4]

Core Insights - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] - The Zacks Momentum Style Score helps investors identify stocks with strong momentum, addressing the challenges of defining momentum [2] Company Overview: Verastem (VSTM) - Verastem currently holds a Momentum Style Score of A, indicating strong momentum potential [3] - The company has a Zacks Rank of 2 (Buy), suggesting it is positioned for outperformance in the market [4] Performance Metrics - Over the past week, VSTM shares increased by 7.58%, while the Zacks Medical - Biomedical and Genetics industry remained flat [6] - In the last quarter, VSTM shares rose by 50.16%, and over the past year, they gained 211.49%, significantly outperforming the S&P 500, which increased by 6.14% and 15.41% respectively [7] Trading Volume - VSTM's average 20-day trading volume is 1,758,705 shares, indicating a bullish sign as rising stocks with above-average volume are generally viewed positively [8] Earnings Outlook - In the past two months, one earnings estimate for VSTM has increased, while none have decreased, leading to a consensus estimate improvement from -$3.11 to -$2.44 [10] - For the next fiscal year, one estimate has moved upwards with no downward revisions, indicating positive earnings momentum [10] Conclusion - Considering the strong performance metrics and positive earnings outlook, VSTM is recommended as a 2 (Buy) stock with a Momentum Score of A, making it a compelling option for investors seeking short-term gains [12]